Retatrutide ZPHC — 120 mg (5 vials × 24 mg)

Retatrutide — triple agonist (GLP-1 / GIP / GCGR)
5 lyophilised vials × 24 mg (total 120 mg)

• Triple-pathway action: simultaneous GLP-1, GIP & glucagon-receptor activation delivers superior appetite suppression, elevated energy expenditure and rapid fat-loss.
• Once-weekly research dosing: extended half-life supports a single sub-Q injection per week.
• Reconstitution: add 2 ml bacteriostatic water → 12 mg/ml; swirl gently, avoid foaming. Store at 2–8 °C.
• Titration guide (research): Week 1–4 → 0.5 mg • Week 5–8 → 1 mg • escalate to 2.5 mg weekly if well-tolerated. Increase gradually to minimise GI effects.
• Pharma-grade QC: ≥ 99 % purity, endotoxin < 0.03 EU/mg; each box includes a scratch-code for authenticity verification.
• Cold-chain packed • tamper-evident vials • discreet, tracked worldwide delivery.